Zamzurina Abu Bakar Malaysia

Dr. Zamzurina Binti Abu Bakar is a Respiratory Consultant at Institut Perubatan Respiratori, Kuala Lumpur. She obtained her MB BCh BAO from the Royal College of Surgeons in Ireland in 2000, completed her Master’s in Internal Medicine at Universiti Kebangsaan Malaysia in 2009, and later pursued a Respiratory Fellowship with the Ministry of Health Malaysia in 2014. She has extensive experience in respiratory medicine, with particular expertise in tuberculosis, drug-resistant tuberculosis, and broader lung health. Over the years, she has been actively involved in numerous international and local research projects, including studies on tuberculosis treatment, chronic cough, bronchiectasis, asthma, COPD, lung cancer genomics, and artificial intelligence applications in TB diagnosis. In addition to her clinical and research work, Dr. Zamzurina has contributed widely at national and institutional levels. She has served in key leadership and advisory roles within the Ministry of Health Malaysia and Institut Perubatan Respiratori, including participating in national TB technical working groups, supervising respiratory fellowship trainees, spirometry trainer and contributing to the development of national clinical practice guidelines, especially in tuberculosis and drug-resistant tuberculosis. Dr. Zamzurina is also an active speaker, educator, reviewer, and author, with publications and lectures focused largely on tuberculosis, respiratory medicine, and public health. She continues to play an important role in advancing respiratory care, research, and TB control in Malaysia.
Job Title
Consultant Respiratory Physician
Faculty / Department / Division
Institut Perubatan Respiratori
Institution / Organisation
Institut Perubatan Respiratori

20 November 2026, Friday

Time Session
09:30
11:00
Bazli Bahar Chairperson Malaysia
  • Diego Silva Speaker Australia
  • Zamzurina Abu Bakar Speaker Malaysia
    Malaysia’s transition from toxic, 20-month injectable regimens to 6-month all-oral BPaLM therapy has revolutionized drug-resistant tuberculosis management, cutting treatment duration by 70%, reducing drug costs by 80%, and shortening median culture conversion to just 32 days while averting irreversible ototoxicity. Coupled with nationwide decentralized molecular testing and genomic resistance surveillance, this operational framework delivers a proven, patient-centred model for reimagining drug-resistant respiratory care across the Asia-Pacific.
  • Mat Zuki Bin Mat Jaeb Speaker Malaysia
    From Control to Elimination: Evaluating Malaysia’s Tuberculosis Journey and Future Priorities Dato’ Dr Mat Zuki Mat Jaeb Abstract Tuberculosis (TB) remains a significant public health challenge in Malaysia despite sustained national control efforts and improvements in treatment outcomes. In 2025, Malaysia reported 26,672 TB cases, corresponding to a notification rate of 77.9 per 100,000 population, while 2,392 deaths highlighted persistent challenges in reducing TB mortality. These findings underscore the need to accelerate progress towards the World Health Organization’s End TB targets. This lecture evaluates Malaysia’s TB epidemiological trends, achievements, persistent gaps, and strategic priorities for transitioning from disease control towards elimination. Key challenges include delayed diagnosis, ongoing community transmission, undetected TB infection, inadequate preventive treatment coverage, comorbidities, population mobility, and disparities in healthcare access. Although treatment success remains encouraging, conventional approaches focusing predominantly on diagnosing and treating active disease are insufficient to interrupt transmission and achieve elimination targets. Malaysia’s National Strategic Plan to End TB 2021–2030 provides the foundation for strengthening early case detection, rapid molecular diagnosis, drug-resistant TB management, contact investigation, preventive treatment, and health system capacity. The Lung Health Initiative Malaysia 2025–2030 further supports an integrated, dual-track strategy addressing both TB infection and active disease through targeted screening, artificial intelligence-assisted chest radiography, shorter treatment regimens, and coordinated healthcare delivery. Achieving TB elimination requires a paradigm shift towards proactive prevention, earlier diagnosis, equitable access, multisectoral collaboration, and measurable program outcomes. Integrating TB services within broader lung health strategies offers Malaysia an opportunity to accelerate progress towards ending TB. Sustained political commitment, adequate financing, community engagement, and robust surveillance will be essential to translate national strategies into impact.
  • Q&A
Ballroom 2, Lower Ground Floor
12:30
16:30

21 November 2026, Saturday